[Status report on the chemotherapy of ovarian cancer at special cancer centers in Hungary (2002-2003)].

Data on the first-line treatment of ovarian cancer in special centers of Hungary 2002 and 2003 are presented, involving 283 and 416 patients, respectively. Patients' age, clinical stage and histological type of the tumor were highly similar to literature data, while grades were different. Surgical effectiveness in case of IIIc staged tumors with >1 cm residual mass was 37%.

[Role of Caelyx in second line treatment of ovarian cancer].

The authors published their own experiences and results of Caelyx treatment based on 40 ovarian cancer patients treated in 9 different institutions. Patients had been treated with platinum based or platinum-taxol combination chemoterapy. Their average age was 57.

[Ovulation induction therapy and malignant ovarian cancer].

In the authors' institute 1097 patients received treatment for ovarian cancer between the 1st of January, 1960 and the 31st of December, 1997. 92 of them had malignant granulosa cell tumor. In this study the link between ovulation induction therapy and ovarian cancer was analyzed with retrospective questionnaire.

[Therapeutic results in patients with malignant granulosa cell tumors at the Gynecologic Clinic of the city of Pécs].

In the Department of Obstetrics and Gynecology, University Medical School of Pecs, Hungary 92 patients had been treated with malignant human granulosa cell tumor between 1960-1997. The youngest patient was 14 years old, the oldest 77. The average age was 52.

[Quality assurance, audit and quality control of radiotherapy at radiology departments in Hungary].

The first quality assurance, audit and control system in the Hungarian "'health" care industry" is described for the medical specialty of radiotherapy. The prerequisites of the elaboration of the programme were an exact knowledge of the current Hungarian infrastructural and staffing conditions, and the radiotherapeutic activities. The recommendations cover the 5 medical universities including the national institute (the Debrecen, Pécs, Semmelweis, Szent-Györgyk Albert Medical Universities, and Haynal Imre University of Health Sciences) and the 5 regional oncological centres in hospitals (Jósa András, Markusovszky, Petz Aladár, Szentpéteri kapu and Uzsoki Hospitals).

Closure or non-closure of visceral peritoneums after abdominal hysterectomies and Wertheim-Meigs radical abdominal hysterectomies.

The effect of visceral peritoneal closure after conventional abdominal hysterectomies and Wertheim-Meigs radical operations was studied clinically. No considerable differences were found in the postoperative staying period; however, the incidence of complications were less in the peritoneal non-closure group (n = 91) than in the control, peritonealized group (n = 149). Significantly lower was the number of postoperative irregular pyelogram in cases without peritoneal closure (n = 25) of radical abdominal operations than in the control group (n = 49) with peritoneal suturing.

[Treatment of patients with advanced ovarian cancer at the Gynecological Clinic of Pécs Medical University].

Treatment protocols for advanced ovarian tumors (stages III-IV), applied at the author's institute, are presented. Giving a short survey the outcome with single agent cyclophosphamide therapy (C; n = 82), combinations without cisplatin (CMV, CAV; n = 83) or combination with cisplatin (CAP; n = 41) has been compared. A significant difference between C and CMV/CAV groups could be found only in regards with remission period (p = 0.

Placental protein 4 as a possible tumor marker in ovarian tumors.

Placental protein 4 (PP-4), a recently characterized glycoprotein from human placenta, was studied using a specific double-antibody radioimmunoassay in sera of 130 volunteers, 76 ovarian tumor patients and in ovarian tumor cyst fluid and ascites of 21 patients. Elevated levels (greater than 3 micrograms/l) were found in 45 of 52 ovarian cancer patients (86.5%).

[Effect of 2 different forms of chemotherapy on remission in patients with advanced ovarian cancer].

Results of combined treatment with two different drug combinations were compared in 82 patients with advanced ovarian carcinoma (stages III-IV). 41 patients received cyclophosphamide, methotrexate, vincristine (CMV) and the other 41 patients were treated with cyclophosphamide, adriamycin and cisplatin (CAP). 34 patients (82.

[Treatment of cervical cancer using the Wertheim-Latzko radical operation at the Gynecology Clinic of Pécs].

The authors performed 119 Wertheim--Latzko operations from July 1, 1975 to December 31, 1988. 108 patients are still alive. The 5 years survival rate of patients operated on before 1984 was 89.

[Dysgerminoma of the ovary. An analysis of 30 cases].

30 patients with ovarian dysgerminoma are reported. Whenever possible the patients were operated radically. In cases when dissemination occurred, exploration was performed.

Occurrence of CA 125 and CA 19-9 tumor-associated antigens in sera of patients with gynecologic, trophoblastic, and colorectal tumors.

The present study was undertaken to test the parallel detectability of ovarian cancer antigen CA 125 and gastrointestinal cancer antigen CA 19-9 in the sera of patients with malignant ovarian tumors, benign ovarian tumors, endometrial cancers, cervical cancers, colorectal cancers, and trophoblastic tumors and in early 1st-trimester pregnant as well as in healthy nonpregnant controls. In all kinds of gynecologic and colorectal tumors raised concentrations of both antigens were found with the exception of malignant nonepithelial ovarian tumors where neither of the antigens showed positive reaction. The most positive cases were found in the group with epithelial ovarian cancers.

Herpes simplex virus-specific antigens in exfoliated cervical cells from women with and without cervical anaplasia.

By the indirect immunofluorescence technique the presence of herpes simplex virus-specific antigens was investigated in cervical cells of 530 women with normal cervical epithelium, 175 with bland disorders, 52 with dysplasias, and 38 with invasive cervical carcinomas of the uterine cervix. Antigens were present in 9% of samples from women with normal cervical epithelium; they were present in 41% of the samples from women with bland disorders, 61% of those from dysplasia patients, and 94% of those from invasive carcinoma patients. The testing of 3 consecutive imprints of 68 antigen-positive and 232 antigen-negative women at 6-month intervals revealed that, in cervical cells, herpesvirus-specific antigens persisted throughout the 1-year period of the follow-up.